Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1986-05-28
1990-08-21
Nucker, Christine M.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
43524021, 43524026, 43524027, 4351722, 435 7021, 436548, 935 95, 935 99, 935100, 935103, 935104, C12P 2100, C12N 500, C21N 3353
Patent
active
049505955
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to a mouse-human hybridoma which produces an antivirus-human antibody, a process for the preparation thereof, and an antivirushuman monoclonal antibody.
It is an object of this invention to provide a mouse-human hybridoma which produces an antivirus-human antibody that is useful for making a diagnosis and providing a cure for viral diseases caused by herpes simplex virus (HSV), varicella zoster virus (VZV), cytomegalo virus (CMV), influenza virus, rabies fixed virus, Japanese encephalitis virus, myxovirus (causing epidemic parotitis), hepatitis B virus (HBV), rotavirus, etc.
It is another object of this invention to provide an anti HSV human monoclonal antibody which is useful for making a diagnosis and providing a cure for viral diseases caused by HSV type 1 or 2. It is another object of the present invention to provide a human monoclonal antibody which reacts specifically to VZV and is useful for making a diagnosis and providing a cure for viral diseases caused by VZV.
BACKGROUND ART
It is a publicly known method to establish hybridoma (fused cell) which continuously produces and secrets a specific antibody by fusing a lymph corpuscle, or a B cell (an antibody-producing cell), which produces a specific antibody but is destined to perish in due course of time, with a myeloma cell, which continues to proliferate indefinitely in a culture medium, by utilizing the art of cell fusion. A monoclonal antibody produced by the hybridoma obtained according to such an art can be used as a pure chemical reagent of high accuracy and reliability and offers applications as a testing reagent, labelling reagent, and also in affinity chromatography. It is further expected to be used as drugs to cure and prevent various diseases.
It is accepted as general knowledge that an attempt to obtain a monoclonal virus antibody can be achieved by using a virus antibody-producing cell with a myeloma cell to give hybridoma, which is producible of a virus antibody, by cloning. Its concrete example is shown in Japanese patent application No. 2276/84, which discloses a process wherein a BALB/C mouse spleen cell, which is immunized to influenza virus or virus of rabies, is fused with a myeloma cell of a mouse of the same species to obtain a hybridoma, which is then subjected to cloning to give a hybridoma which produces a monoclonal antivirus-mouse antibody. Japanese patent application Laid-open No. 175489/83 also discloses that hybridoma which produces antiherpes simplex virus-mouse antibody was obtained by fusing a spleen cell of a mouse immunized to herpes simplex virus with a mouse myeloma cell.
As described in the above, definitely successful cases of antivirus antibody-producing hybridomas are limited only to the mouse-mouse hybridomas which produce antivirus-mouse antibodies. However, in case of making a diagnosis and providing a cure for human being disease, the use of an antivirus-human antibody comprising the homogeneous proteins is absolutely useful and safe, and this can be realized only by the established formation of a mouse-human hybridoma or a human-human hybridoma obtained by use of anti-body-producing cells of a human being. In the case of a human being, however, being different from the case of animals, there are problems which face us with difficulty of obtaining proper antibody-producing cells since it can not be arranged with ease to have a human being immunized to a large amount of viruses to get effectively stimulated antibody-producing cells for the desired cell fusion use, and there have been no reports made yet on definitely successful practices.
DISCLOSURE OF INVENTION
As the result of intensive research work made on obtaining mouse-human hybridomas producible of antivirus-human antibody, the present inventors have made it possible to obtain antivirus-human antibody-producing mouse-human hybridoma by the method of allowing a human antibody-producing cell sensitized with virus or protein, or glycoprotein arising from virus, to fuse with a mouse myeloma cell in
REFERENCES:
patent: 4574116 (1986-03-01), Kaplan
patent: 4634666 (1987-01-01), Engleman et al.
Campbell Laboratory Techniques in Biochem. & Mol. Biology, vol. 13, Elsevier, Amsterdam, 1984, pp. 94-99.
Okuno, T. et al. Virology 129, pp. 357-368, 1983.
Nowinski et al., Science, 120, pp. 537-539, 1980.
Foung, S. et al., J. Inf. Diseases 152, pp. 280-285, 1985.
Masuho Yasuhiko
Matsumoto Yoh-ichi
Sugano Toru
Tomibe Katsuhiko
Krupen Karen I.
Nucker Christine M.
Teijin Limited
LandOfFree
Mouse-human hybridoma which produces antivirus-human antibody, p does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mouse-human hybridoma which produces antivirus-human antibody, p, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mouse-human hybridoma which produces antivirus-human antibody, p will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1677217